Research at Oslo University Hospital


Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.


Latest news

Collaboration to identify novel biomarkers that can predict whether a patient will respond positively to pembrolizumab


The Norwegian bioinformatics company OncoImmunity and the Norwegian Cancer Genomics Consortium (NCGC) at Oslo University Hospital announce September 20th that they have entered into a collaboration with the American "Sarcoma Alliance for Research through Collaboration" (, to search for active neoantigens and related immune biomarker signatures of response in an American clinical trial on sarcoma patients treated with the PD1 immune checkpoint inhibitor pembrolizumab.


Sept 29th - Information day about EMBL, EMBO and HSPF:

Scientific opportunities in Europe


This event is open to all, and is designed to help inform Norwegian scientists about the training opportunities, services and infrastructure available at the EMBL (European Molecular Biology Laboratory). The meeting is sponsored by the EMBL Alumni Association, and has received funding from UiO: Life Science and the Research Council of Norway.  
Date & Time: 9am-6pm, Friday 29 September 2017
Location: University Library Auditorium 1, Georg Sverdrup Hus, Blindern, University of Oslo.


Scandic Holmenkollen Park, December 4-6, 2017:

The Norwegian Cancer symposium 2017 on Precision Medicine


We would like to extend an invitation to The Norwegian Cancer symposium 2017 on Precision Medicine
It will take place at Scandic Holmenkollen Park, December 4-6, 2017 in Oslo, Norway.

The meeting gathers leading national and international speakers in the field of precision medicine, and topics include the following:

  • Computational Cancer Genomics
  • Tumor Immunology and the microenvironment
  • Single cell analysis for disease trajectories and Liquid Biopsies
  • Monitoring cancer genetics in body fluids
  • Translational and clinical genomics

Jahre lecture Thursday September 14th

Inst. head H. Stenmark and Christer Betsholtz
Inst. head H. Stenmark and Christer Betsholtz

On Thursday September 14th The Institute for Cancer Research had the honour of hosting this year´s Jahre Prize winners for their lectures.
The lectures were by three of the leading scientists in the Nordic countries. The main prize winner (Christer Betsholtz) and one of the junior prize winners (Simon Bekker-Jensen) have their background in cancer research.


Anne-Lise Børresen-Dale appointed Commander of the Royal Norwegian St. Olavs Order


His Majesty The King has appointed Professor Emerita Anne-Lise Børresen-Dale as Commander of the Royal Norwegian St. Olavs Order for her outstanding efforts in medical research.
The decoration was be presented at an event in the Research Building at Radium Hospital in Oslo August 28.


ERC Starting Grant 2017 to Kyrre Eeg Emblem


The European Research Council (ERC) has awarded a Starting Grant 2017 to Kyrre Eeg Emblem from Department of Diagnostic Physics at the Divsion of Radiology & Nuclear Medicine. This is the seventh ERC Starting Grant awarded to Norway in the main panel Life Sciences (LS), and the first time Oslo University Hospital is the host institution.


Tone Rustøen "Researcher of the Month" for July

Tone Rustøen
Tone Rustøen

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has appointed Tone Rustøen from the Nursing Research Group at the Division of Emergencies and Critical Care at Oslo University Hospital as "Researcher of the month" for the month of July.


Call for applications 2018

Annuncement of research funding from South-East Norway regional health authority for 2018


The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2018.

The total funding available for this call is approximately 100 million Norwegian kroner.

Application deadline is Tuesday, September 5th 2017 kl. 16:00.


OUH scientists involved in sequencing study of osteosarcoma that has identified mutations in IGF signalling genes

From left: Zaikova, Bjerkehagen and Myklebost
From left: Zaikova, Bjerkehagen and Myklebost

A portion of bone cancers may respond to existing insulin-like growth factor 1 receptor inhibitors because they carry mutations in IGF signaling genes, a study recently published in Nature Communications suggests. The sarcoma team at the Norwegian Radium Hospital at Oslo University Hospital was represented in this study by Bodil Bjerkehagen, the sarcoma reference pathologist, Olga Zaikova, on behalf of the orthopedists, and Ola Myklebost, PI in the ICGC Bone Cancer Project. This study is a side branch from their previous participation in the European Network of Excellence on Bone Tumours, and is carried out by the International Cancer Genomics Consortium at the Sanger Centre in Hinxton outside Cambridge.


Håvard Danielsen appointed "Scientist of the Month" by "Helse Sør-Øst" for June 2017

Håvard Danielsen
Håvard Danielsen

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".

For the month of June 2017, this honour went to professor Håvard Danielsen, head of the Institute for Cancer Genetics and Informatics at OUH.